Literature DB >> 18524822

Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture.

Kimberley A Zimmerman1, Karl P Fischer, Michael A Joyce, D Lorne J Tyrrell.   

Abstract

Duck hepatitis B virus (DHBV) is a model virus for human hepatitis B virus (HBV), which infects approximately 360 million individuals worldwide. Nucleoside analogs can decrease virus production by inhibiting the viral polymerase; however, complete clearance by these drugs is not common because of the persistence of the HBV episome. HBV DNA is present in the nucleus as a covalently closed circular (cccDNA) form, where it drives viral transcription and progeny virus production. cccDNA is not the direct target of antiviral nucleoside analogs and is the source of HBV reemergence when antiviral therapy is stopped. To target cccDNA, six different zinc finger proteins (ZFP) were designed to bind DNA sequences in the DHBV enhancer region. After the binding kinetics were assessed by using electrophoretic mobility shift assays and surface plasmon resonance, two candidates with dissociation constants of 12.3 and 40.2 nM were focused on for further study. The ZFPs were cloned into a eukaryotic expression vector and cotransfected into longhorn male hepatoma cells with the plasmid pDHBV1.3, which replicates the DHBV life cycle. In the presence of each ZFP, viral RNA was significantly reduced, and protein levels were dramatically decreased. As a result, intracellular viral particle production was also significantly decreased. In summary, designed ZFPs are able to bind to the DHBV enhancer and interfere with viral transcription, resulting in decreased production of viral products and progeny virus genomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524822      PMCID: PMC2519588          DOI: 10.1128/JVI.00366-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences.

Authors:  D J Segal; B Dreier; R R Beerli; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors.

Authors:  B Dreier; R R Beerli; D J Segal; J D Flippin; C F Barbas
Journal:  J Biol Chem       Date:  2001-05-04       Impact factor: 5.157

3.  A detailed study of the substrate specificity of a chimeric restriction enzyme.

Authors:  J Smith; J M Berg; S Chandrasegaran
Journal:  Nucleic Acids Res       Date:  1999-01-15       Impact factor: 16.971

4.  Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells.

Authors:  P A Knolle; E Schmitt; S Jin; T Germann; R Duchmann; S Hegenbarth; G Gerken; A W Lohse
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment.

Authors:  A Limmer; T Sacher; J Alferink; M Kretschmar; G Schönrich; T Nichterlein; B Arnold; G J Hämmerling
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

6.  Regulatory sequences of duck hepatitis B virus C gene transcription.

Authors:  R Schneider; H Will
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks.

Authors:  R R Beerli; D J Segal; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Identification of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations.

Authors:  C Liu; W S Mason; J B Burch
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors:  A Severini; X Y Liu; J S Wilson; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.

Authors:  E V Genovesi; L Lamb; I Medina; D Taylor; M Seifer; S Innaimo; R J Colonno; D N Standring; J M Clark
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

View more
  38 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

3.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.

Authors:  Jieliang Chen; Wen Zhang; Junyu Lin; Fan Wang; Min Wu; Cuncun Chen; Ye Zheng; Xiuhua Peng; Jianhua Li; Zhenghong Yuan
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

Review 4.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 5.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

6.  TALENs targeting HBV: designer endonuclease therapies for viral infections.

Authors:  Nicholas D Weber; Daniel Stone; Keith R Jerome
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

Review 7.  Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.

Authors:  Abdullah Ely; Buhle Moyo; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

Review 8.  Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

Authors:  Samantha A Nicholson; Buhle Moyo; Patrick B Arbuthnot
Journal:  World J Hepatol       Date:  2015-04-28

Review 9.  Eradication Strategies for Chronic Hepatitis B Infection.

Authors:  Eleanor M P Wilson; Lydia Tang; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

10.  MicroRNA-203 enhances coxsackievirus B3 replication through targeting zinc finger protein-148.

Authors:  Maged Gomaa Hemida; Xin Ye; Huifang M Zhang; Paul J Hanson; Zhen Liu; Bruce M McManus; Decheng Yang
Journal:  Cell Mol Life Sci       Date:  2012-07-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.